Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultra low-dose decitabine in elderly AML or higher-risk MDS
ChiCTR-OPC-17011617Phase 4Not yet recruiting
- Sponsor
- Anshan Central Hospital
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of decitabine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by Anshan Central Hospital. Primary endpoint: overall response rate. Planned start Jul 2017; status: not yet recruiting.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on ChiCTR-OPC-17011617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17011617.